Agomab Therapeutics director David R. Epstein reports $103,500 common share acquisition

Director David R. Epstein purchased 15,000 Agomab Therapeutics common shares, increasing his direct holdings to 40,000 shares. He paid $6.81, $6.91 and $6.98 per share for 5,000 shares at each price.